Clinical efficacy of tolterodine with or without a simplified pelvic floor exercise regimen

To investigate whether the combination of tolterodine plus (Tp) a simple pelvic floor muscle exercise (PFME) program would provide improved treatment benefits compared with tolterodine alone (Ta) in patients with symptoms of overactive bladder (OAB).

[1]  U. Jonas,et al.  Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder. , 2002, European urology.

[2]  J. Wyndaele,et al.  Tolterodine reduces the number of urge incontinence episodes in patients with an overactive bladder. , 2001, European journal of obstetrics, gynecology, and reproductive biology.

[3]  B. Shaffu,et al.  Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial. , 2001 .

[4]  C. Payne.  Behavioral therapy for overactive bladder. , 2000 .

[5]  L. Berghmans,et al.  Nonpharmacologic treatments for overactive bladder-pelvic floor exercises. , 2000, Urology.

[6]  A. Mattiasson,et al.  OVERACTIVE BLADDER AND ITS TREATMENTS—QUESTIONS AND ANSWERS AFTER CHRISTOPHER K. PAYNE, K. BØ, AND ANDERS MATTIASSON , 2000, Urology.

[7]  J. Ouslander,et al.  Effects of Urge Urinary Incontinence on Quality of Life in Older People , 1999, Journal of the American Geriatrics Society.

[8]  J. Susset,et al.  Clinical efficacy and safety of tolterodine compared to placebo in detrusor overactivity. , 1999, The Journal of urology.

[9]  P. Goode,et al.  Behavioral vs drug treatment for urge urinary incontinence in older women: a randomized controlled trial. , 1998, JAMA.

[10]  U. Jonas,et al.  Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation , 1998, World Journal of Urology.

[11]  P. Abrams,et al.  Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. , 1998, British journal of urology.

[12]  R. Appell.  Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis. , 1997, Urology.

[13]  R A Sherman,et al.  Behavioral treatment of exercise-induced urinary incontinence among female soldiers. , 1997, Military medicine.

[14]  T. Talseth,et al.  Long‐Term Effect of Pelvic Floor Muscle Exercise 5 Years After Cessation of Organized Training , 1996, Obstetrics and gynecology.

[15]  C. van Weel,et al.  The effects of treatment of urinary incontinence in general practice. , 1992, Family practice.

[16]  T. Nochajski,et al.  Treatment of Stress Incontinence with Pelvic Floor Exercises and Biofeedback , 1990, Journal of the American Geriatrics Society.

[17]  Tolterodine , 2002 .

[18]  P. Abrams,et al.  Twelve-Month Treatment of Overactive Bladder , 2001, Drugs & aging.

[19]  A. Mattiasson.  Characterisation of lower urinary tract disorders: A new view , 2001, Neurourology and urodynamics.

[20]  S. Radomski,et al.  Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder , 1999, International Urogynecology Journal.

[21]  N. Resnick,et al.  Outcome measures for research of lower urinary tract dysfunction in frail older people , 1998, Neurourology and urodynamics.

[22]  U. Jonas,et al.  Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation. The International Study Group. , 1997, World journal of urology.

[23]  K. Kreder,et al.  Efficacy of pelvic floor muscle exercises in women with stress, urge, and mixed urinary incontinence , 1996, American journal of obstetrics and gynecology.